Global Oncology


Edus H. Warren, MD, PhD, Program Head, Global Oncology

Dr. Edus H. Warren

Photo by Robert Hood / Fred Hutch News Service

Edus H. Warren, MD, PhD
Program Head, Global Oncology

Dr. Edus H. Warren is the Head of Fred Hutch Global Oncology. Dr. Warren, who prefers to go by “Hootie,” assumed leadership of the program in July 2017. Dr. Warren is an oncologist specializing in the treatment of patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. He is an Attending Physician at the Seattle Cancer Care Alliance, where he serves on both the Hematology/Hematologic Malignancy and the Hematopoietic Cell Transplant Services.

Dr. Warren’s research interests are focused on cancer immunotherapy. He has considerable experience as an investigator on clinical trials of novel agents for the treatment of blood cancers, and served as the Principal Investigator on a Phase I clinical trial of T-cell immunotherapy for patients with relapse of acute leukemia or high-grade myelodysplasia after HLA-identical allogeneic hematopoietic cell transplantation. His laboratory research focuses on several interrelated areas, including: high-throughput sequencing of T- and B-cell antigen receptor repertoires; the immunobiology of lymphoma (particularly Burkitt lymphoma and HIV-associated non-Hodgkin lymphoma) and Kaposi sarcoma in sub-Saharan Africa; and solid tumor immunobiology and immunotherapy. High priority objectives of this work are to identify tumor antigens that might be targeted with adoptive T-cell therapy, and to understand how to make solid tumor immunotherapy more effective. Dr. Warren seeks to invest in basic and translational research that will lead to innovative strategies for adapting the advances in cancer research, prevention, diagnosis, and treatment made in high-income countries to help address the increasing burden of cancer morbidity and mortality in low- and middle-income countries.

Warren received a Ph.D. in Neurobiology from Harvard University and a M.D. from Harvard Medical School. He completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Medical Oncology at the University of Washington.

Thomas Uldrick, MD, Deputy Head, Global Oncology

Dr. Thomas Uldrick

Photo by Robert Hood / Fred Hutch News Service

Thomas Uldrick, MD, MS
Deputy Head, Global Oncology

A hematologist and oncologist, Dr. Uldrick’s research focuses on AIDS-related cancers, particularly Kaposi sarcoma and lymphoma, both of which are key areas of focus for the Global Oncology program. Prior to his leadership position with Fred Hutch Global Oncology, Uldrick collaborated with Global Oncology scientists in the National Institutes of Health-sponsored AIDS Malignancy Consortium and with the Fred Hutch-based Cancer Immunotherapy Trials Network. With the latter, he is a lead scientist in a multicenter study of pembrolizumab (Keytruda), a type of immunotherapy known as a checkpoint inhibitor, in people with both HIV and cancer. Uldrick has worked in southern Africa and aims to design clinical trials, including immunotherapy studies, for low-resource countries.

Prior Fred Hutch, Uldrick was a Senior Clinician and Clinical Director of the HIV & AIDS Malignancy Branch at the Center for Cancer Research at the National Cancer Institute. Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa. Uldrick develops and directs early phase clinical studies and biomarker-driven natural history studies in KSHV-associated malignancies and cancer in people with HIV, including Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, primary CNS lymphoma, and anal cancer. He has published important studies on the pathogenesis of IL-6 related syndromes in the setting of HIV and KSHV co-infection, and HIV-associated cancers in resource-limited settings. Current therapeutic studies incorporate cytokine and growth factor manipulation, immune modulation, and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antibodies or virus activated cytotoxic therapy.

Uldrick is an associate member of VIDD in the Clinical Research Division and as an associate professor in the Department of Medicine at the University Of Washington School Of Medicine.

Sarah Ewart, Managing Director, Fred Hutch Global Oncology

Sarah Ewart, MBA, MSc

Photo by Robert Hood / Fred Hutch News Service

Sarah Ewart, MBA, MSc
Managing Director, Global Oncology
President, Hutchinson Centre Research Institute of Uganda

As Managing Director of Fred Hutch Global Oncology and President of the Hutchinson Centre Research Institute of Uganda, Sarah Ewart shapes strategy, advances public and private partnership development, and promotes new initiatives. Ms. Ewart directs the program’s external affairs and development activities and oversees the program's administrative and financial operations in the US and Uganda.

Most recently, Ms. Ewart consulted for private companies and non-profit organizations advancing global health research and product development. She has also worked for the Bill & Melinda Gates Foundation, PATH, the US Agency for International Development, and the Peace Corps.

Ms. Ewart holds an MBA from the University of Washington’s Foster School of Business and an MSc in International Development Studies from the London School of Economics and Political Science.